Bracco Diagnostics Inc. Updates Product Portfolio

Bracco Diagnostics Inc. (BDI), a U.S. subsidiary of Bracco Imaging S.p.A., renowned in the diagnostic imaging industry, has announced a significant update on its barium product offerings as part of a strategic review. The initiative aims to strengthen its product lineup, driven by the needs of healthcare providers and patients.

BDI has embarked on this project to expand and innovate its barium portfolio. Part of this initiative includes seeking FDA approval for a new product, with plans to submit for approval within the year. Upon receiving expected approval, BDI will present an enhanced suite of FDA-approved barium products tailored for abdominal imaging requirements.

Cosimo De Pinto, Senior Vice President of Sales and Marketing at BDI, emphasized the company's commitment to advancing the field of barium and oral imaging. He stated, "Our continuous investment in new and expanded product offerings demonstrates our dedication to supporting healthcare providers in delivering exceptional patient care."

Concurrently, due to market and procedural changes, BDI will discontinue three non-FDA-approved barium products. This decision follows a notable decrease in their usage. Importantly, BDI does not foresee the discontinuation of any additional barium products.

De Pinto further elaborated, "Ensuring that we provide high-quality diagnostic imaging solutions to our customers is crucial. This rationalization process was necessary to allocate our resources effectively to meet the evolving needs of the medical community."

In its pursuit of innovation, BDI has provided a preview of its upcoming product launches over the next 24 months. This includes CitraClear™, a beverage aimed at improving patient satisfaction during imaging preparation, to be released in Q3 2024. Following in Q4 2024, the VARIBAR® (barium sulfate) "Mini" packaging will offer more convenient and sustainable options for healthcare facilities. In 2025, BDI plans to introduce a new flavor to its CT barium line, further enhancing the patient experience during imaging procedures.

BDI encourages healthcare providers and industry partners to explore its evolving barium pipeline and looks forward to ongoing collaboration in advancing diagnostic imaging technologies.

BDI's product portfolio includes VARIBAR® THIN HONEY, VARIBAR® NECTAR, and VARIBAR® THIN LIQUID, which are barium sulfate oral suspensions used in modified barium swallow examinations to assess oral and pharyngeal functions in both adults and children. Additionally, VARIBAR® HONEY and VARIBAR® PUDDING are designed for similar diagnostic purposes in patients aged six months and older.

It is noteworthy that these products should not be used in patients with certain gastrointestinal conditions, such as known or suspected perforations, obstructions, or those at high risk of aspiration. Adverse reactions can include nausea, vomiting, and more severe conditions such as aspiration pneumonitis and intestinal perforation.

Bracco Imaging S.p.A., headquartered in Milan, Italy, is a global leader in diagnostic imaging solutions, covering modalities like X-ray, MRI, CEUS, and Nuclear Medicine. With around 3,600 employees worldwide and operations in over 100 markets, Bracco Imaging continues to innovate within the industry. Their research and development (R&D) efforts are robust, with centers located in Italy, Switzerland, the United Kingdom, and the United States. In 2020, Bracco Group reported global revenues of 1.4 billion Euros.